US headquartered venture secondary investor Omega Funds has acquired a portfolio of nine life sciences companies from Lombard Odier, a Swiss private bank.
The companies, based in the US and Europe, are part of a series of direct secondary deals Omega has completed recently, in total acquiring 25 businesses for over US$125m.
Omega was founded in 2004 and manages five funds, all dedicated to making direct secondary transactions in the healthcare space, with a specific focus on venture capital and growth equity.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: